美国dMMR/MSI-H晚期或复发子宫内膜癌一线帕博利珠单抗单药治疗的真实世界结局
这项回顾性队列研究利用Flatiron Health数据库,纳入228例dMMR/MSI-H晚期或复发子宫内膜癌患者,比较一线帕博利珠单抗单药(80例)与卡铂-紫杉醇(148例)的真实世界结局。帕博利珠单抗组中位rwTOT为9.1个月,卡铂-紫杉醇组为3.5个月;中位rwTTNT分别为16.6个月和5.8个月。在既往接受过铂类治疗的患者中,帕博利珠单抗同样显示更长的rwTOT和rwTTNT。
要点
- 帕博利珠单抗组中位rwTOT为9.1个月,化疗组为3.5个月。
- 帕博利珠单抗组中位rwTTNT为16.6个月,化疗组为5.8个月。
- 既往铂类治疗亚组中帕博利珠单抗仍显示更优的rwTOT和rwTTNT。
核心结论
- 真实世界结果表明帕博利珠单抗可能是dMMR/MSI-H晚期或复发子宫内膜癌的有效无化疗选择。
- 正在进行的KEYNOTE-C93试验(NCT05173987)将提供确证性证据。
研究设计与样本
- 回顾性队列研究,使用Flatiron Health Research Database(2013年1月1日至2025年6月30日)。
- 纳入228例成人dMMR/MSI-H晚期或复发子宫内膜癌患者,2017年5月1日或之后开始一线帕博利珠单抗单药(80例)或卡铂-紫杉醇(148例)治疗。
- 采用Kaplan-Meier法估计真实世界治疗持续时间(rwTOT)和至下次治疗或死亡时间(rwTTNT)。
主要发现
- 中位年龄范围为65至70岁;大多数患者为子宫内膜样组织学(86.3%)和复发疾病(78.8%)。
- 帕博利珠单抗组中位rwTOT为9.1个月(95% CI: 5.1-14.5),卡铂-紫杉醇组为3.5个月(95% CI: 3.4-3.5)。
- 帕博利珠单抗组中位rwTTNT为16.6个月(95% CI: 9.4-32.3),卡铂-紫杉醇组为5.8个月(95% CI: 5.4-6.2)。
- 在既往接受新辅助/辅助铂类治疗的患者(n=41)中,帕博利珠单抗组(n=31,75.6%)rwTOT为12.2个月(95% CI: 4.9-23.5),rwTTNT为23.1个月(95% CI: 7.2-NE);卡铂-紫杉醇组(n=10,24.4%)rwTOT为3.1个月(95% CI: 0.0-3.7),rwTTNT为5.4个月(95% CI: 1.9-15.2)。
临床怎么用
- 对于dMMR/MSI-H晚期或复发子宫内膜癌患者,一线帕博利珠单抗单药可能作为无化疗选择,尤其适用于既往接受过铂类治疗者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Describe real-world outcomes among patients with dMMR/MSI-H advanced or recurrent endometrial cancer (EC) treated with first-line (1 L) pembrolizumab monotherapy or carboplatin-paclitaxel. METHODS: This retrospective cohort study used the Flatiron Health Research Database (January 1, 2013-June 30, 2025). Adult patients with dMMR/MSI-H advanced or recurrent EC who initiated pembrolizumab monotherapy or carboplatin-paclitaxel as 1 L therapy on or after May 1, 2017, were included. Real-world time on treatment (rwTOT) and time to next treatment or death (rwTTNT) were estimated using Kaplan-Meier methods overall and by prior neoadjuvant/adjuvant platinum therapy. RESULTS: Of the 228 patients included, 80 received pembrolizumab and 148 carboplatin-paclitaxel. Median age ranged from 65 to 70 years; most patients had endometrioid histology (86.3%) and recurrent disease (78.8%). Among patients with prior neoadjuvant/adjuvant platinum therapy n = 41, 75.6% (n = 31) received pembrolizumab and (n = 10) 24.4% received carboplatin-paclitaxel. Median rwTOT (months) was 9.1 (95% CI: 5.1-14.5) for pembrolizumab and 3.5 (95% CI: 3.4-3.5) for carboplatin-paclitaxel. Median rwTTNT was 16.6 (95% CI: 9.4-32.3) for pembrolizumab and 5.8 (95% CI: 5.4-6.2) for carboplatin-paclitaxel. Among patients with prior platinum therapy, rwTOT and rwTTNT were 12.2 (95% CI: 4.9-23.5) and 23.1 (95% CI: 7.2-NE) for pembrolizumab, and 3.1 (95% CI: 0.0-3.7) and 5.4 (95% CI: 1.9-15.2) for carboplatin-paclitaxel. CONCLUSIONS: These real-world findings suggest pembrolizumab may be an effective chemotherapy-free option for patients with dMMR/MSI-H advanced or recurrent EC. Confirmatory evidence from the ongoing KEYNOTE-C93 trial (NCT05173987) will help inform its efficacy in this setting.
引用
- McClain KM, Prabhu VS, Marupuru S, et al. Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States. Gynecol Oncol. 2026. PMID: 42855328. doi:10.1016/j.ygyno.2026.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。